Kadmon Holdings, Inc.
Kadmon Holdings, Inc. KDMN Peers
See (KDMN) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| KDMN | $9.50 | N/A | 0 | -13.32 | -$0.71 | N/A |
| VRTX | $446.00 | +2.29% | 114.5B | -116.15 | -$3.84 | N/A |
| REGN | $603.26 | +2.54% | 64B | 15.33 | $39.36 | +0.30% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $290.10 | +0.05% | 37.8B | -138.80 | -$2.09 | N/A |
| ARGX | $579.77 | -1.33% | 35.4B | 35.37 | $16.39 | N/A |
| BNTX | $98.55 | -0.13% | 23.7B | -27.30 | -$3.61 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| SMMT | $25.63 | -0.85% | 18.9B | -75.38 | -$0.34 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
KDMN vs VRTX Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, VRTX has a market cap of 114.5B. Regarding current trading prices, KDMN is priced at $9.50, while VRTX trades at $446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas VRTX's P/E ratio is -116.15. In terms of profitability, KDMN's ROE is -0.77%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, KDMN is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs REGN Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, REGN has a market cap of 64B. Regarding current trading prices, KDMN is priced at $9.50, while REGN trades at $603.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas REGN's P/E ratio is 15.33. In terms of profitability, KDMN's ROE is -0.77%, compared to REGN's ROE of +0.15%. Regarding short-term risk, KDMN is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs SGEN Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, KDMN is priced at $9.50, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas SGEN's P/E ratio is -57.19. In terms of profitability, KDMN's ROE is -0.77%, compared to SGEN's ROE of -0.17%. Regarding short-term risk, KDMN is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for KDMN.
KDMN vs ALNY Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, ALNY has a market cap of 37.8B. Regarding current trading prices, KDMN is priced at $9.50, while ALNY trades at $290.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas ALNY's P/E ratio is -138.80. In terms of profitability, KDMN's ROE is -0.77%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, KDMN is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs ARGX Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, ARGX has a market cap of 35.4B. Regarding current trading prices, KDMN is priced at $9.50, while ARGX trades at $579.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas ARGX's P/E ratio is 35.37. In terms of profitability, KDMN's ROE is -0.77%, compared to ARGX's ROE of +0.16%. Regarding short-term risk, KDMN is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs BNTX Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, BNTX has a market cap of 23.7B. Regarding current trading prices, KDMN is priced at $9.50, while BNTX trades at $98.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas BNTX's P/E ratio is -27.30. In terms of profitability, KDMN's ROE is -0.77%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, KDMN is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs BGNE Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, KDMN is priced at $9.50, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas BGNE's P/E ratio is -22.55. In terms of profitability, KDMN's ROE is -0.77%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, KDMN is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs SMMT Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, SMMT has a market cap of 18.9B. Regarding current trading prices, KDMN is priced at $9.50, while SMMT trades at $25.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas SMMT's P/E ratio is -75.38. In terms of profitability, KDMN's ROE is -0.77%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, KDMN is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs DNA-WT Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, KDMN is priced at $9.50, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, KDMN's ROE is -0.77%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, KDMN is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs RPRX Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, RPRX has a market cap of 18.4B. Regarding current trading prices, KDMN is priced at $9.50, while RPRX trades at $32.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas RPRX's P/E ratio is 13.34. In terms of profitability, KDMN's ROE is -0.77%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, KDMN is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs UTHR Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, UTHR has a market cap of 14.2B. Regarding current trading prices, KDMN is priced at $9.50, while UTHR trades at $314.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas UTHR's P/E ratio is 12.54. In terms of profitability, KDMN's ROE is -0.77%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, KDMN is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs GMAB Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, GMAB has a market cap of 13.1B. Regarding current trading prices, KDMN is priced at $9.50, while GMAB trades at $21.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas GMAB's P/E ratio is 12.52. In terms of profitability, KDMN's ROE is -0.77%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, KDMN is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs INCY Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, INCY has a market cap of 12.6B. Regarding current trading prices, KDMN is priced at $9.50, while INCY trades at $65.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas INCY's P/E ratio is 326.65. In terms of profitability, KDMN's ROE is -0.77%, compared to INCY's ROE of +0.01%. Regarding short-term risk, KDMN is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs KRTX Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, KDMN is priced at $9.50, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas KRTX's P/E ratio is -28.09. In terms of profitability, KDMN's ROE is -0.77%, compared to KRTX's ROE of -0.25%. Regarding short-term risk, KDMN is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for KDMN.
KDMN vs EXEL Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, EXEL has a market cap of 11.8B. Regarding current trading prices, KDMN is priced at $9.50, while EXEL trades at $43.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas EXEL's P/E ratio is 19.68. In terms of profitability, KDMN's ROE is -0.77%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, KDMN is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs BMRN Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, KDMN is priced at $9.50, while BMRN trades at $58.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas BMRN's P/E ratio is 21.52. In terms of profitability, KDMN's ROE is -0.77%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, KDMN is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs MRNA Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, MRNA has a market cap of 10.3B. Regarding current trading prices, KDMN is priced at $9.50, while MRNA trades at $26.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas MRNA's P/E ratio is -3.07. In terms of profitability, KDMN's ROE is -0.77%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, KDMN is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs RXDX Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, KDMN is priced at $9.50, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas RXDX's P/E ratio is -56.47. In terms of profitability, KDMN's ROE is -0.77%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, KDMN is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for KDMN.
KDMN vs ASND Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, ASND has a market cap of 9.5B. Regarding current trading prices, KDMN is priced at $9.50, while ASND trades at $157.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas ASND's P/E ratio is -23.90. In terms of profitability, KDMN's ROE is -0.77%, compared to ASND's ROE of +1.91%. Regarding short-term risk, KDMN is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs IMGN Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, KDMN is priced at $9.50, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas IMGN's P/E ratio is -111.55. In terms of profitability, KDMN's ROE is -0.77%, compared to IMGN's ROE of +0.05%. Regarding short-term risk, KDMN is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for KDMN.
KDMN vs CERE Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, KDMN is priced at $9.50, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas CERE's P/E ratio is -16.47. In terms of profitability, KDMN's ROE is -0.77%, compared to CERE's ROE of -0.99%. Regarding short-term risk, KDMN is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for KDMN.
KDMN vs CORT Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, CORT has a market cap of 8.1B. Regarding current trading prices, KDMN is priced at $9.50, while CORT trades at $76.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas CORT's P/E ratio is 66.79. In terms of profitability, KDMN's ROE is -0.77%, compared to CORT's ROE of +0.20%. Regarding short-term risk, KDMN is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs ROIVW Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, KDMN is priced at $9.50, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, KDMN's ROE is -0.77%, compared to ROIVW's ROE of -0.02%. Regarding short-term risk, KDMN is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs ROIV Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, ROIV has a market cap of 7.7B. Regarding current trading prices, KDMN is priced at $9.50, while ROIV trades at $10.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas ROIV's P/E ratio is -10.76. In terms of profitability, KDMN's ROE is -0.77%, compared to ROIV's ROE of -0.02%. Regarding short-term risk, KDMN is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs TECH Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, TECH has a market cap of 7.6B. Regarding current trading prices, KDMN is priced at $9.50, while TECH trades at $48.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas TECH's P/E ratio is 58.65. In terms of profitability, KDMN's ROE is -0.77%, compared to TECH's ROE of +0.06%. Regarding short-term risk, KDMN is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs RVMD Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, RVMD has a market cap of 6.9B. Regarding current trading prices, KDMN is priced at $9.50, while RVMD trades at $36.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas RVMD's P/E ratio is -9.22. In terms of profitability, KDMN's ROE is -0.77%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, KDMN is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs JAZZ Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, JAZZ has a market cap of 6.7B. Regarding current trading prices, KDMN is priced at $9.50, while JAZZ trades at $109.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas JAZZ's P/E ratio is 14.86. In terms of profitability, KDMN's ROE is -0.77%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, KDMN is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs HALO Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, HALO has a market cap of 6.7B. Regarding current trading prices, KDMN is priced at $9.50, while HALO trades at $54.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas HALO's P/E ratio is 14.48. In terms of profitability, KDMN's ROE is -0.77%, compared to HALO's ROE of +1.22%. Regarding short-term risk, KDMN is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs RETA Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, KDMN is priced at $9.50, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas RETA's P/E ratio is -66.29. In terms of profitability, KDMN's ROE is -0.77%, compared to RETA's ROE of +0.47%. Regarding short-term risk, KDMN is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for KDMN.
KDMN vs BPMC Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, BPMC has a market cap of 6.5B. Regarding current trading prices, KDMN is priced at $9.50, while BPMC trades at $100.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas BPMC's P/E ratio is -39.85. In terms of profitability, KDMN's ROE is -0.77%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, KDMN is less volatile compared to BPMC. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs VRNA Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, VRNA has a market cap of 6.4B. Regarding current trading prices, KDMN is priced at $9.50, while VRNA trades at $75.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas VRNA's P/E ratio is -37.80. In terms of profitability, KDMN's ROE is -0.77%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, KDMN is less volatile compared to VRNA. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs BBIO Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, BBIO has a market cap of 6.3B. Regarding current trading prices, KDMN is priced at $9.50, while BBIO trades at $33.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas BBIO's P/E ratio is -9.30. In terms of profitability, KDMN's ROE is -0.77%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, KDMN is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs MDGL Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, MDGL has a market cap of 6B. Regarding current trading prices, KDMN is priced at $9.50, while MDGL trades at $271.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas MDGL's P/E ratio is -15.23. In terms of profitability, KDMN's ROE is -0.77%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, KDMN is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs TLX Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, TLX has a market cap of 5.7B. Regarding current trading prices, KDMN is priced at $9.50, while TLX trades at $16.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas TLX's P/E ratio is 187.11. In terms of profitability, KDMN's ROE is -0.77%, compared to TLX's ROE of +0.14%. Regarding short-term risk, KDMN is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs TGTX Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, TGTX has a market cap of 5.6B. Regarding current trading prices, KDMN is priced at $9.50, while TGTX trades at $35.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas TGTX's P/E ratio is 140.96. In terms of profitability, KDMN's ROE is -0.77%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, KDMN is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs ABCM Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, KDMN is priced at $9.50, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, KDMN's ROE is -0.77%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, KDMN is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for KDMN.
KDMN vs ISEE Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, KDMN is priced at $9.50, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas ISEE's P/E ratio is -22.44. In terms of profitability, KDMN's ROE is -0.77%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, KDMN is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs IONS Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, IONS has a market cap of 5.3B. Regarding current trading prices, KDMN is priced at $9.50, while IONS trades at $33.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas IONS's P/E ratio is -11.14. In terms of profitability, KDMN's ROE is -0.77%, compared to IONS's ROE of -0.00%. Regarding short-term risk, KDMN is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs NUVL Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, NUVL has a market cap of 5.2B. Regarding current trading prices, KDMN is priced at $9.50, while NUVL trades at $72.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas NUVL's P/E ratio is -16.35. In terms of profitability, KDMN's ROE is -0.77%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, KDMN is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs AXSM Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, AXSM has a market cap of 5.1B. Regarding current trading prices, KDMN is priced at $9.50, while AXSM trades at $103.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas AXSM's P/E ratio is -18.02. In terms of profitability, KDMN's ROE is -0.77%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, KDMN is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs ALKS Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, ALKS has a market cap of 4.9B. Regarding current trading prices, KDMN is priced at $9.50, while ALKS trades at $29.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas ALKS's P/E ratio is 14.23. In terms of profitability, KDMN's ROE is -0.77%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, KDMN is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs ADMA Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, ADMA has a market cap of 4.7B. Regarding current trading prices, KDMN is priced at $9.50, while ADMA trades at $19.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas ADMA's P/E ratio is 23.68. In terms of profitability, KDMN's ROE is -0.77%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, KDMN is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs ALPN Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, KDMN is priced at $9.50, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas ALPN's P/E ratio is -101.52. In terms of profitability, KDMN's ROE is -0.77%, compared to ALPN's ROE of -0.15%. Regarding short-term risk, KDMN is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for KDMN.
KDMN vs OPT Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, KDMN is priced at $9.50, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas OPT's P/E ratio is -1.52. In terms of profitability, KDMN's ROE is -0.77%, compared to OPT's ROE of +2.60%. Regarding short-term risk, KDMN is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for KDMN.
KDMN vs MRTX Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, KDMN is priced at $9.50, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas MRTX's P/E ratio is -4.82. In terms of profitability, KDMN's ROE is -0.77%, compared to MRTX's ROE of -0.40%. Regarding short-term risk, KDMN is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs PCVX Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, PCVX has a market cap of 4.1B. Regarding current trading prices, KDMN is priced at $9.50, while PCVX trades at $31.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas PCVX's P/E ratio is -7.95. In terms of profitability, KDMN's ROE is -0.77%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, KDMN is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs SLNO Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, SLNO has a market cap of 3.8B. Regarding current trading prices, KDMN is priced at $9.50, while SLNO trades at $76.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas SLNO's P/E ratio is -16.09. In terms of profitability, KDMN's ROE is -0.77%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, KDMN is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs PTCT Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, PTCT has a market cap of 3.8B. Regarding current trading prices, KDMN is priced at $9.50, while PTCT trades at $47.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas PTCT's P/E ratio is 7.35. In terms of profitability, KDMN's ROE is -0.77%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, KDMN is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs SRPT Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, SRPT has a market cap of 3.8B. Regarding current trading prices, KDMN is priced at $9.50, while SRPT trades at $38.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas SRPT's P/E ratio is -14.52. In terms of profitability, KDMN's ROE is -0.77%, compared to SRPT's ROE of -0.20%. Regarding short-term risk, KDMN is less volatile compared to SRPT. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs RYTM Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, RYTM has a market cap of 3.8B. Regarding current trading prices, KDMN is priced at $9.50, while RYTM trades at $59.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas RYTM's P/E ratio is -21.14. In terms of profitability, KDMN's ROE is -0.77%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, KDMN is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs RYZB Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, KDMN is priced at $9.50, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas RYZB's P/E ratio is -57.86. In terms of profitability, KDMN's ROE is -0.77%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, KDMN is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for KDMN.
KDMN vs CBAY Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, KDMN is priced at $9.50, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas CBAY's P/E ratio is -32.81. In terms of profitability, KDMN's ROE is -0.77%, compared to CBAY's ROE of -0.32%. Regarding short-term risk, KDMN is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for KDMN.
KDMN vs ACAD Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, KDMN is priced at $9.50, while ACAD trades at $22.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas ACAD's P/E ratio is 16.20. In terms of profitability, KDMN's ROE is -0.77%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, KDMN is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs AKRO Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, AKRO has a market cap of 3.7B. Regarding current trading prices, KDMN is priced at $9.50, while AKRO trades at $46.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas AKRO's P/E ratio is -12.27. In terms of profitability, KDMN's ROE is -0.77%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, KDMN is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs RNA Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, RNA has a market cap of 3.7B. Regarding current trading prices, KDMN is priced at $9.50, while RNA trades at $30.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas RNA's P/E ratio is -10.12. In terms of profitability, KDMN's ROE is -0.77%, compared to RNA's ROE of -0.27%. Regarding short-term risk, KDMN is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs KRYS Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, KRYS has a market cap of 3.7B. Regarding current trading prices, KDMN is priced at $9.50, while KRYS trades at $126.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas KRYS's P/E ratio is 30.40. In terms of profitability, KDMN's ROE is -0.77%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, KDMN is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs CYTK Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, CYTK has a market cap of 3.6B. Regarding current trading prices, KDMN is priced at $9.50, while CYTK trades at $30.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas CYTK's P/E ratio is -5.77. In terms of profitability, KDMN's ROE is -0.77%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, KDMN is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs MRUS Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, MRUS has a market cap of 3.5B. Regarding current trading prices, KDMN is priced at $9.50, while MRUS trades at $50.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas MRUS's P/E ratio is -12.19. In terms of profitability, KDMN's ROE is -0.77%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, KDMN is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs SWTX Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, KDMN is priced at $9.50, while SWTX trades at $46.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas SWTX's P/E ratio is -13.62. In terms of profitability, KDMN's ROE is -0.77%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, KDMN is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for KDMN.
KDMN vs ACLX Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, ACLX has a market cap of 3.4B. Regarding current trading prices, KDMN is priced at $9.50, while ACLX trades at $62.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas ACLX's P/E ratio is -20.75. In terms of profitability, KDMN's ROE is -0.77%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, KDMN is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs RARE Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, RARE has a market cap of 3.3B. Regarding current trading prices, KDMN is priced at $9.50, while RARE trades at $35.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas RARE's P/E ratio is -6.02. In terms of profitability, KDMN's ROE is -0.77%, compared to RARE's ROE of -1.86%. Regarding short-term risk, KDMN is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs CRSP Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, CRSP has a market cap of 3.2B. Regarding current trading prices, KDMN is priced at $9.50, while CRSP trades at $37.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas CRSP's P/E ratio is -8.37. In terms of profitability, KDMN's ROE is -0.77%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, KDMN is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs VKTX Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, VKTX has a market cap of 3.1B. Regarding current trading prices, KDMN is priced at $9.50, while VKTX trades at $27.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas VKTX's P/E ratio is -23.43. In terms of profitability, KDMN's ROE is -0.77%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, KDMN is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs CPRX Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, CPRX has a market cap of 3B. Regarding current trading prices, KDMN is priced at $9.50, while CPRX trades at $24.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas CPRX's P/E ratio is 15.82. In terms of profitability, KDMN's ROE is -0.77%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, KDMN is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs MTSR Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, MTSR has a market cap of 2.9B. Regarding current trading prices, KDMN is priced at $9.50, while MTSR trades at $27.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas MTSR's P/E ratio is -10.96. In terms of profitability, KDMN's ROE is -0.77%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, KDMN is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs SRRK Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, SRRK has a market cap of 2.9B. Regarding current trading prices, KDMN is priced at $9.50, while SRRK trades at $30.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas SRRK's P/E ratio is -11.95. In terms of profitability, KDMN's ROE is -0.77%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, KDMN is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs PTGX Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, PTGX has a market cap of 2.9B. Regarding current trading prices, KDMN is priced at $9.50, while PTGX trades at $46.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas PTGX's P/E ratio is 59.53. In terms of profitability, KDMN's ROE is -0.77%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, KDMN is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs MORF Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, KDMN is priced at $9.50, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas MORF's P/E ratio is -14.88. In terms of profitability, KDMN's ROE is -0.77%, compared to MORF's ROE of -0.27%. Regarding short-term risk, KDMN is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for KDMN.
KDMN vs MOR Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, KDMN is priced at $9.50, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas MOR's P/E ratio is -12.64. In terms of profitability, KDMN's ROE is -0.77%, compared to MOR's ROE of +7.43%. Regarding short-term risk, KDMN is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs CRNX Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, CRNX has a market cap of 2.8B. Regarding current trading prices, KDMN is priced at $9.50, while CRNX trades at $29.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas CRNX's P/E ratio is -7.76. In terms of profitability, KDMN's ROE is -0.77%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, KDMN is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs KDNY Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, KDMN is priced at $9.50, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas KDNY's P/E ratio is -12.47. In terms of profitability, KDMN's ROE is -0.77%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, KDMN is less volatile compared to KDNY. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs LEGN Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, LEGN has a market cap of 2.6B. Regarding current trading prices, KDMN is priced at $9.50, while LEGN trades at $28.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas LEGN's P/E ratio is -24.37. In terms of profitability, KDMN's ROE is -0.77%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, KDMN is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs MYOV Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, KDMN is priced at $9.50, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas MYOV's P/E ratio is -14.05. In terms of profitability, KDMN's ROE is -0.77%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, KDMN is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for KDMN.
KDMN vs MLTX Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, MLTX has a market cap of 2.4B. Regarding current trading prices, KDMN is priced at $9.50, while MLTX trades at $38.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas MLTX's P/E ratio is -16.77. In terms of profitability, KDMN's ROE is -0.77%, compared to MLTX's ROE of -0.00%. Regarding short-term risk, KDMN is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs IMVT Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, IMVT has a market cap of 2.4B. Regarding current trading prices, KDMN is priced at $9.50, while IMVT trades at $14.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas IMVT's P/E ratio is -5.45. In terms of profitability, KDMN's ROE is -0.77%, compared to IMVT's ROE of -0.78%. Regarding short-term risk, KDMN is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs PRVB Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, KDMN is priced at $9.50, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas PRVB's P/E ratio is -16.43. In terms of profitability, KDMN's ROE is -0.77%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, KDMN is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for KDMN.
KDMN vs LBPH Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, KDMN is priced at $9.50, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas LBPH's P/E ratio is -26.66. In terms of profitability, KDMN's ROE is -0.77%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, KDMN is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for KDMN.
KDMN vs DICE Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, KDMN is priced at $9.50, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas DICE's P/E ratio is -21.91. In terms of profitability, KDMN's ROE is -0.77%, compared to DICE's ROE of +0.56%. Regarding short-term risk, KDMN is less volatile compared to DICE. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs XENE Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, XENE has a market cap of 2.3B. Regarding current trading prices, KDMN is priced at $9.50, while XENE trades at $29.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas XENE's P/E ratio is -9.15. In terms of profitability, KDMN's ROE is -0.77%, compared to XENE's ROE of -0.32%. Regarding short-term risk, KDMN is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs BCRX Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, BCRX has a market cap of 2.3B. Regarding current trading prices, KDMN is priced at $9.50, while BCRX trades at $10.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas BCRX's P/E ratio is -41.50. In terms of profitability, KDMN's ROE is -0.77%, compared to BCRX's ROE of +0.11%. Regarding short-term risk, KDMN is less volatile compared to BCRX. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs AAPG Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, AAPG has a market cap of 2.3B. Regarding current trading prices, KDMN is priced at $9.50, while AAPG trades at $25.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas AAPG's P/E ratio is -35.07. In terms of profitability, KDMN's ROE is -0.77%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, KDMN is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs IBRX Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, IBRX has a market cap of 2.2B. Regarding current trading prices, KDMN is priced at $9.50, while IBRX trades at $2.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas IBRX's P/E ratio is -4.44. In terms of profitability, KDMN's ROE is -0.77%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, KDMN is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs APGE Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, KDMN is priced at $9.50, while APGE trades at $36.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas APGE's P/E ratio is -10.22. In terms of profitability, KDMN's ROE is -0.77%, compared to APGE's ROE of -0.19%. Regarding short-term risk, KDMN is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs VCYT Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, VCYT has a market cap of 2.2B. Regarding current trading prices, KDMN is priced at $9.50, while VCYT trades at $27.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas VCYT's P/E ratio is 66.57. In terms of profitability, KDMN's ROE is -0.77%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, KDMN is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs MIRM Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, MIRM has a market cap of 2.2B. Regarding current trading prices, KDMN is priced at $9.50, while MIRM trades at $43.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas MIRM's P/E ratio is -27.25. In terms of profitability, KDMN's ROE is -0.77%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, KDMN is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs CALT Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, KDMN is priced at $9.50, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas CALT's P/E ratio is -22.73. In terms of profitability, KDMN's ROE is -0.77%, compared to CALT's ROE of -2.10%. Regarding short-term risk, KDMN is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs APLS Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, APLS has a market cap of 2.1B. Regarding current trading prices, KDMN is priced at $9.50, while APLS trades at $16.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas APLS's P/E ratio is -9.38. In terms of profitability, KDMN's ROE is -0.77%, compared to APLS's ROE of -1.00%. Regarding short-term risk, KDMN is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs ARWR Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, ARWR has a market cap of 2.1B. Regarding current trading prices, KDMN is priced at $9.50, while ARWR trades at $15.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas ARWR's P/E ratio is -12.40. In terms of profitability, KDMN's ROE is -0.77%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, KDMN is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs VCEL Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, KDMN is priced at $9.50, while VCEL trades at $42.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas VCEL's P/E ratio is 841.40. In terms of profitability, KDMN's ROE is -0.77%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, KDMN is less volatile compared to VCEL. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs BLTE Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, BLTE has a market cap of 2B. Regarding current trading prices, KDMN is priced at $9.50, while BLTE trades at $61.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas BLTE's P/E ratio is -44.96. In terms of profitability, KDMN's ROE is -0.77%, compared to BLTE's ROE of -0.31%. Regarding short-term risk, KDMN is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs LGND Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, LGND has a market cap of 2B. Regarding current trading prices, KDMN is priced at $9.50, while LGND trades at $101.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas LGND's P/E ratio is -13.95. In terms of profitability, KDMN's ROE is -0.77%, compared to LGND's ROE of -0.16%. Regarding short-term risk, KDMN is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs CGON Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, CGON has a market cap of 1.9B. Regarding current trading prices, KDMN is priced at $9.50, while CGON trades at $25.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas CGON's P/E ratio is -17.01. In terms of profitability, KDMN's ROE is -0.77%, compared to CGON's ROE of -0.17%. Regarding short-term risk, KDMN is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs HRMY Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, HRMY has a market cap of 1.9B. Regarding current trading prices, KDMN is priced at $9.50, while HRMY trades at $33.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas HRMY's P/E ratio is 12.90. In terms of profitability, KDMN's ROE is -0.77%, compared to HRMY's ROE of +0.24%. Regarding short-term risk, KDMN is less volatile compared to HRMY. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs KNSA Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, KNSA has a market cap of 1.9B. Regarding current trading prices, KDMN is priced at $9.50, while KNSA trades at $26.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas KNSA's P/E ratio is -110.33. In terms of profitability, KDMN's ROE is -0.77%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, KDMN is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs FOLD Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, FOLD has a market cap of 1.9B. Regarding current trading prices, KDMN is priced at $9.50, while FOLD trades at $6.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas FOLD's P/E ratio is -69.39. In terms of profitability, KDMN's ROE is -0.77%, compared to FOLD's ROE of -0.17%. Regarding short-term risk, KDMN is less volatile compared to FOLD. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs DNLI Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, DNLI has a market cap of 1.9B. Regarding current trading prices, KDMN is priced at $9.50, while DNLI trades at $13.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas DNLI's P/E ratio is -4.95. In terms of profitability, KDMN's ROE is -0.77%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, KDMN is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs NAMS Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, NAMS has a market cap of 1.9B. Regarding current trading prices, KDMN is priced at $9.50, while NAMS trades at $17.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas NAMS's P/E ratio is -9.24. In terms of profitability, KDMN's ROE is -0.77%, compared to NAMS's ROE of -0.26%. Regarding short-term risk, KDMN is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs GLPG Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, GLPG has a market cap of 1.9B. Regarding current trading prices, KDMN is priced at $9.50, while GLPG trades at $28.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas GLPG's P/E ratio is -9.38. In terms of profitability, KDMN's ROE is -0.77%, compared to GLPG's ROE of -0.06%. Regarding short-term risk, KDMN is less volatile compared to GLPG. This indicates potentially lower risk in terms of short-term price fluctuations for KDMN.
KDMN vs BLU Comparison
KDMN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KDMN stands at 0. In comparison, BLU has a market cap of 1.9B. Regarding current trading prices, KDMN is priced at $9.50, while BLU trades at $14.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KDMN currently has a P/E ratio of -13.32, whereas BLU's P/E ratio is -20.20. In terms of profitability, KDMN's ROE is -0.77%, compared to BLU's ROE of -0.06%. Regarding short-term risk, KDMN is more volatile compared to BLU. This indicates potentially higher risk in terms of short-term price fluctuations for KDMN.